source
- Incyte reports positive Phase 3 results for povorcitinib in nonsegmental vitiligo, plans FDA filingIncyte announced that its oral JAK1 inhibitor povorcitinib achieved positive outcomes in two Phase 3 trials targeting nonsegmental vitiligo. The studies met their primary endpoints, demonstrating…
- AbbVie eyes pan-RAS market with up to $1.45 B option to acquire KestrelAbbVie announced it has signed an agreement that gives it the right to acquire Kestrel Therapeutics for up to $1.45 billion. The deal would give AbbVie access to Kestrel’s pipeline focused on pan-…